Modified immune cells aim to make stem cell transplants safer
NCT ID NCT06034535
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tests a new method to improve stem cell transplants for people with blood disorders who lack a fully matched donor. Researchers will give patients specially processed donor immune cells (CD62L-depleted lymphocytes) alongside a T-cell depleted stem cell transplant. The goal is to reduce complications like graft failure and graft-versus-host disease, while improving survival. The study enrolls 23 participants and follows them for one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD62L-depleted donor lymphocytes
- What this could lead to
- If successful, this approach could reduce the risk of graft failure and severe graft-versus-host disease, making haploidentical transplants safer and more effective for patients without a matched donor.
- What could go wrong
- This is a small, early-phase trial (23 participants) testing a complex cell therapy. The treatment may not improve outcomes, and risks include infection, graft failure, or severe immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC ORGANS; DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hong Kong Children's Hospital
RECRUITINGHong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.